Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
Helena Chaytow, Kiterie M. E. Faller, Yu-Ting Huang, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 7, pp. 100346-100346
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Base editing rescue of spinal muscular atrophy in cells and in mice
Mandana Arbab, Żaneta Matuszek, Kaitlyn M. Kray, et al.
Science (2023) Vol. 380, Iss. 6642
Open Access | Times Cited: 88
Advances and limitations for the treatment of spinal muscular atrophy
John Day, Kelly Howell, Amy Place, et al.
BMC Pediatrics (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 78
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Hisahide Nishio, Emma Tabe Eko Niba, Toshio Saito, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11939-11939
Open Access | Times Cited: 62
Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
Claudia A. Chiriboga, Claudio Bruno, Tina Duong, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 543-557
Open Access | Times Cited: 39
A spinal muscular atrophy modifier implicates the SMN protein in SNARE complex assembly at neuromuscular synapses
Jeong-Ki Kim, Narendra Nath Jha, Tomoyuki Awano, et al.
Neuron (2023) Vol. 111, Iss. 9, pp. 1423-1439.e4
Open Access | Times Cited: 23
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges
Sherif Bayoumy, Inge M.W. Verberk, Lisa Vermunt, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 7, pp. 1252-1265
Open Access | Times Cited: 16
Significance of Programmed Cell Death Pathways in Neurodegenerative Diseases
Dong Guo, Zhihao Liu, Jinglin Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 9947-9947
Open Access | Times Cited: 11
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis
Kiterie M. E. Faller, Helena Chaytow, Thomas H. Gillingwater
Nature Reviews Neurology (2025) Vol. 21, Iss. 2, pp. 86-102
Closed Access | Times Cited: 1
Alterations in cardiac function correlate with a disruption in fatty acid metabolism in a mouse model of SMA
Nandini Nair, Rachel Kline, I. E. Boyd, et al.
Human Molecular Genetics (2025)
Open Access | Times Cited: 1
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1865-1883
Open Access | Times Cited: 38
How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action
Anne‐Marie Baird, C. Benedikt Westphalen, Sandra M. Blum, et al.
Health Science Reports (2023) Vol. 6, Iss. 6
Open Access | Times Cited: 18
Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints
Mary M. Reilly, David N. Herrmann, Davide Pareyson, et al.
Annals of Neurology (2023) Vol. 93, Iss. 5, pp. 906-910
Open Access | Times Cited: 17
Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment
Silvia Bonanno, Paola Cavalcante, Erika Salvi, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 24
The Role of Transposable Elements of the Human Genome in Neuronal Function and Pathology
Ekaterina Chesnokova, Alexander Beletskiy, П. М. Колосов
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5847-5847
Open Access | Times Cited: 23
Dysfunctional mitochondria accumulate in a skeletal muscle knockout model of Smn1, the causal gene of spinal muscular atrophy
Francesco Chemello, Michela Pozzobon, Lorenza Iolanda Tsansizi, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 15
The SMN-ribosome interplay: a new opportunity for Spinal Muscular Atrophy therapies
Gaurav Sharma, Martina Paganin, Fabio Lauria, et al.
Biochemical Society Transactions (2024) Vol. 52, Iss. 1, pp. 465-479
Open Access | Times Cited: 5
Administration of adipose-derived stem cells extracellular vesicles in a murine model of spinal muscular atrophy: effects of a new potential therapeutic strategy
Federica Virla, Ermanna Turano, Ilaria Scambi, et al.
Stem Cell Research & Therapy (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
Jiaying Qiu, Liucheng Wu, Ruobing Qu, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 20
AMPK is mitochondrial medicine for neuromuscular disorders
Andrew I. Mikhail, Sean Y. Ng, Stephanie R. Mattina, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 7, pp. 512-529
Open Access | Times Cited: 11
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Umme Sabrina Haque, Toshifumi Yokota
Genes (2024) Vol. 15, Iss. 8, pp. 999-999
Open Access | Times Cited: 4
Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases
Giulia Paolini Sguazzi, Valentina Muto, Marco Tartaglia, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13674-13674
Open Access | Times Cited: 24
Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2–4
Marloes Stam, Camiel A. Wijngaarde, Bart Bartels, et al.
Brain Communications (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 18
Timing is everything: Clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy
Anna A. L. Motyl, Thomas H. Gillingwater
Cell Reports Medicine (2022) Vol. 3, Iss. 8, pp. 100725-100725
Open Access | Times Cited: 17
An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Yueyi Li, Hongyu Zeng, Yuhao Wei, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 5-6, pp. 180-191
Closed Access | Times Cited: 10
Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot–Marie–Tooth type 2A
Federica Rizzo, Silvia Bono, Marc David Ruepp, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 12
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top